Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions

American Journal of Psychiatry

Volumn 168, Issue 4, 2011, Pages 418-426

  Woodward, Neil D ^a,b,c,d,e   Cowan, Ronald L ^a,b,c,d   Park, Sohee ^a,b,c,d   Ansari, M Sib ^a,b,c,d   Baldwin, Ronald M ^a,b,c,d   Li, Rui ^a,b,c,d   Doop, Mikisha ^a,b,c,d   Kessler, Robert M ^a,b,c,d   Zald, David H ^a,b,c,d  

^a Psychiatric Neuroimaging Program   (United States)

^b Department of Psychology ^*  (United States)

^c Institute of Imaging Science   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE;

ADULT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; FRONTAL GYRUS; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; INSULA; MALE; NORMAL HUMAN; PERSONALITY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOTYPAL PERSONALITY QUESTIONNAIRE; SCHIZOTYPAL PERSONALITY TRAIT; SUPRAMARGINAL GYRUS; TEMPORAL LOBE; THALAMUS; VOLUNTEER;

ADULT; AMPHETAMINE; BRAIN; CORPUS STRIATUM; DOPAMINE; FEMALE; FRONTAL LOBE; HUMANS; INDIVIDUALITY; MALE; PERSONALITY INVENTORY; POSITRON-EMISSION TOMOGRAPHY; SCHIZOTYPAL PERSONALITY DISORDER; SINGLE-BLIND METHOD; TEMPORAL LOBE; THALAMUS; YOUNG ADULT;

EID: 79955135948     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10020165     Document Type: Article

References (48)

1. Widiger TA, Mullins-Sweatt SN: Five-factor model of personality disorder: a proposal for DSM-V. Annu Rev Clin Psychol 2009;5:197-220
2. Raine A: The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991;17:555-564
3. Compton MT, Goulding SM, Bakeman R, Clure-Tone EB: Confirmation of a four-factor structure of the Schizotypal Personality Questionnaire among undergraduate students. Schizophr Res 2009;111:46-52
4. Gruzelier JH: The factorial structure of schizotypy, part I: affinities with syndromes of schizophrenia. Schizophr Bull 1996;22:611-620 (Pubitemid 26389407)
5. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH: Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009;35:894-908
6. Kendler KS, Gruenberg AM, Strauss JS: An independent analysis of the Copenhagen sample of the Danish Adoption Study of Schizophrenia, V: the relationship between childhood social withdrawal and adult schizophrenia. Arch Gen Psychiatry 1982;39:1257-1261 (Pubitemid 13232304)
7. Ott SL, Roberts S, Rock D, Allen J, Erlenmeyer-Kimling L: Positive and negative thought disorder and psychopathology in childhood among subjects with adulthood schizophrenia. Schizophr Res 2002;58:231-239 (Pubitemid 35284514)
8. Chen WJ, Hsiao CK, Lin CC: Schizotypy in community samples: the three-factor structure and correlation with sustained attention. J Abnorm Psychol 1997;106:649-654 (Pubitemid 27465282)
9. Noguchi H, Hori H, Kunugi H: Schizotypal traits and cognitive function in healthy adults. Psychiatry Res 2008;161:162-169
10. Bedwell JS, Kamath V, Compton MT: The relationship between interview-based schizotypal personality dimension scores and the Continuous Performance Test. Schizophr Res 2009;108:158-162
11. Wang J, Miyazato H, Hokama H, Hiramatsu K, Kondo T: Correlation between P50 suppression and psychometric schizotypy among non-clinical Japanese subjects. Int J Psychophysiol 2004;52:147-157 (Pubitemid 38402064)
12. Matsui M, Yuuki H, Kato K, Takeuchi A, Nishiyama S, Bilker WB, Kurachi M: Schizotypal disorder and schizophrenia: a profile analysis of neuropsychological functioning in Japanese patients. J Int Neuropsychol Soc 2007;13:672-682 (Pubitemid 350017940)
13. Cadenhead KS, Light GA, Geyer MA, Braff DL: Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry 2000;157:55-59 (Pubitemid 30027421)
14. Croft RJ, Lee A, Bertolot J, Gruzelier JH: Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy. Biol Psychiatry 2001;50:441-446 (Pubitemid 32885594)
15. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ: Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004;55:1001-1006 (Pubitemid 38584612)
16. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R: Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72 (Pubitemid 29296818)
17. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-2574 (Pubitemid 27136916)
18. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G: Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007;27:8080-8087 (Pubitemid 47173328)
19. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B: Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999;46:681-688 (Pubitemid 29401864)
20. Stone JM, Davis JM, Leucht S, Pilowsky LS: Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs: an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009;35:789-797
21. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, Anderson S, Doop M, Woodward N, Schoenberg E, Schmidt D, Baldwin R, Kessler R: Amphetamine-induced displacement of [18F]fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006;31:1016-1026
22. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC, American Psychiatric Press, 1996
23. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P: Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198 (Pubitemid 127762930)
24. Zald DH, Woodward ND, Cowan RL, Riccardi P, Ansari MS, Baldwin RM, Cowan RL, Smith CE, Hakyemez H, Li R, Kessler RM: The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: a principal component analysis of [18F]fallypride binding. Neuroimage 2010;51:53-62
25. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS: Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52
26. Kessler RM, Mason NS, Jones C, Ansari MS, Manning RF, Price RR: [18F]N-ally-5-fluorproplepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. Neuroimage 2000;11: S32
27. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ: Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747 (Pubitemid 20260955)
28. Shattuck DW, Mirza M, Adisetiyo V, Hojatkashani C, Salamon G, Narr KL, Poldrack RA, Bilder RM, Toga AW: Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage 2008;39:1064-1080
29. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamineinduced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285-300 (Pubitemid 36307573)
30. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van HR, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D (2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-1057 (Pubitemid 32823740)
31. Poline JB, Worsley KJ, Evans AC, Friston KJ: Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage 1997;5:83-96 (Pubitemid 27481515)
32. Lancaster JL, Tordesillas-Gutierrez D, Martinez M, Salinas F, Evans A, Zilles K, Mazziotta JC, Fox PT: Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp 2007;28:1194-1205 (Pubitemid 350077483)
33. Daneluzzo E, Bustini M, Stratta P, Casacchia M, Rossi A: Schizotypal Personality Questionnaire and Wisconsin Card Sorting Test in a population of DSM-III-R schizophrenic patients and control subjects. Compr Psychiatry 1998;39:143-148 (Pubitemid 28223922)
34. Vollema MG, Sitskoorn MM, Appels MC, Kahn RS: Does the Schizotypal Personality Questionnaire reflect the biologicalgenetic vulnerability to schizophrenia? Schizophr Res 2002;54:39-45 (Pubitemid 34164517)
35. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ: Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64:628-634 (Pubitemid 36750138)
36. Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J: Striatal dopamine synthesis in firstdegree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-117 (Pubitemid 350234886)
37. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-1486
38. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M: Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22:3708-3719 (Pubitemid 37465776)
39. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M: Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-636
40. Karlsson P, Farde L, Halldin C, Sedvall G: PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002;159:761-767 (Pubitemid 34465049)
41. Yoon JH, Minzenberg MJ, Ursu S, Walters R, Wendelken C, Ragland JD, Carter CS: Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function. Am J Psychiatry 2008;165:1006-1014
42. Moritz S, Andresen B, Naber D, Krausz M, Probsthein E: Neuropsychological correlates of schizotypal disorganization. Cogn Neuropsychiatry 1999;4:343-349
43. Matheson S, Langdon R: Schizotypal traits impact upon executive working memory and aspects of IQ. Psychiatry Res 2008;159:207-214
44. Deutch AY: The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992;36:61-89
45. Sesack SR, Carr DB: Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav 2002;77:513-517 (Pubitemid 36084394)
46. Schneier FR, Abi-Dargham A, Martinez D, Slifstein M, Hwang DR, Liebowitz MR, Laruelle M: Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety 2009;26:411-418
47. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van HR, Mann JJ, Laruelle M: Dopamine D (2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001;50:313-322 (Pubitemid 32816943)
48. Kendler KS, Thacker L, Walsh D: Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia. Schizophr Bull 1996;22:511-520 (Pubitemid 26295353)